Invacare shares are trading higher after the company reported Q4 EPS of $(0.16), beating the $(0.37) estimate and sales of $244.6 million, beating the $240.83 million estimate; the company also issued FY19 EBITDA guidance of $20 million and higher.
Benzinga Newsdesk